Skip to main content

Table. 2 The segmented regression analysis results of the level and trend changes of the monthly proportion of patients who initiated medication with the study medicines before and after September 2017

From: How government health insurance coverage of novel anti-cancer medicines benefited patients in China – a retrospective analysis of hospital clinical data

Constant 95 %CI(lower, upper) p-value γ1 195 %CI(lower, upper) p-value γ2 295 %CI(lower, upper) p-value γ3 395 %CI(lower, upper) p-value
0.22(0.15,0.31) < 0.01 0.092(0.04,0.17) 0.08 0.183(0.104,0.34) 0.01 1.48(1.03,3.60) 0.02
  1. Notes:
  2. γ1indicates the slope of the trend of the monthly proportion of the patients who initiated medication with the study medicines before September 2017;
  3. γ2 indicates the level change of the monthly proportion of the patients who initiated medication with the study medicines within the month of September 2017;
  4. γ3 indicates the slope of the trend of the monthly proportion of patients who initiated medication with the study medicines after September 2017